Anti-Human TNFA & ALB Bispecific Reference Antibody (Ozoralizumab, RUO)

Description: Research Grade Ozoralizumab (BS10039) is a humanized monoclonal antibody detecting TNF in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights:
• Multi-Application — Validated across multiple applications.
Host species: Humanized
Isotype: VH-VH'-VH
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 0.52mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: TNF,Tumornecrosisfactorligandsuperfamilymember2,N-terminalfragment,ICD2,NTF,TNF-a,TNF-alpha,Tumornecrosisfactor,TNFSF2,TNFA,Cachectin,ICD1,ALB,Albumin
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,ATN-103,CAS:1167985-17-2
Background: Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis.
Note: For research use only. Not suitable for clinical or therapeutic use.